All stock lists
Viridian Therapeutics, Inc. DE (NASDAQ:VRDN)
US · Delayed Price · Currency is USD
Also listed: 0K1R.LHealthcare · Biotechnology
22.79+0.41 (+1.86%)
Insider Score
––Not scored
VRDN Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
VRDN Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 284.00 K | 141.00 K | 132.00 K | 70.57 M | 75.00 K | 72.00 K |
| Revenue Growth (YoY) | 278.67 % | 95.83 % | 83.33 % | 81958.14 % | 4.17 % | 0.00 % |
| Cost of Revenue | 0.00 | 0.00 | 320.00 K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 284.00 K | 141.00 K | -188.00 K | 70.57 M | 75.00 K | 72.00 K |
| SG&A Expense | 54.98 M | 38.68 M | 33.67 M | 24.32 M | 20.22 M | 17.10 M |
| R&D Expense | 71.58 M | 77.63 M | 89.21 M | 86.26 M | 86.63 M | 76.83 M |
| Operating Expenses | 126.55 M | 116.31 M | 122.56 M | 110.58 M | 106.84 M | 93.94 M |
| Operating Income | -126.27 M | -116.17 M | -122.75 M | -40.01 M | -106.77 M | -93.87 M |
| Pretax Income | -127.12 M | -104.90 M | -120.36 M | -34.60 M | -100.73 M | -86.91 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -127.12 M | -104.90 M | -120.36 M | -34.60 M | -100.73 M | -86.91 M |
| EPS (Basic) | -1.05 | -1.03 | -1.11 | -0.34 | -1.23 | -0.87 |
| EPS (Diluted) | -1.05 | -1.03 | -1.11 | -0.34 | -1.23 | -0.87 |
| Shares Outstanding | 107.88 M | 102.21 M | 84.80 M | 81.78 M | 81.59 M | 81.34 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.